牛牛AI助手已提取核心信息中国生物制药2025年上半年实现收入175.7亿元人民币，同比增长10.7%；归属于母公司持有者盈利33.9亿元人民币，同比增长140.2%。创新产品收入达到78亿元人民币，同比增长27.2%，占总收入44.4%。期内研发投入31.9亿元人民币，占收入18.1%。董事会宣派中期股息每股5港仙。期内，公司共有2个创新产品获NMPA批准上市，分别为普坦宁（美洛昔康注射液(II...
Source Link牛牛AI助手已提取核心信息中国生物制药2025年上半年实现收入175.7亿元人民币，同比增长10.7%；归属于母公司持有者盈利33.9亿元人民币，同比增长140.2%。创新产品收入达到78亿元人民币，同比增长27.2%，占总收入44.4%。期内研发投入31.9亿元人民币，占收入18.1%。董事会宣派中期股息每股5港仙。期内，公司共有2个创新产品获NMPA批准上市，分别为普坦宁（美洛昔康注射液(II...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.